Amedisys, Inc. (NASDAQ:AMED) Q4 2022 Earnings Conference Call February 16, 2023 11:00 AM ET
Company Participants
Nick Muscato - Chief Strategy Officer
Paul Kusserow - Chairman & CEO
Scott Ginn - EVP, CFO & Acting COO
Adam Holton - Chief People Officer
Conference Call Participants
Brian Tanquilut - Jefferies
Matthew Larew - William Blair & Company
Justin Bowers - Deutsche Bank
Joanna Gajuk - Bank of America Merrill Lynch
Andrew Mok - UBS
Tao Qiu - Stifel, Nicolaus & Company
Benjamin Hendrix - RBC Capital Markets
Benjamin Mayo - SVB Securities
John Ransom - Raymond James & Associates
Scott Fidel - Stephens Inc.
Gary Taylor - Cowen and Company
A.J. Rice - Crédit Suisse
Operator
Greetings and welcome to the Amedisys Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions].
It is now my pleasure to introduce your host, Mr. Nick Muscato, Chief Strategy Officer. Thank you. Please go ahead.
Nick Muscato
Thank you, operator, and welcome to the Amedisys investor conference call to discuss the results of the fourth quarter and year ended December 31, 2022. A copy of our press release, supplemental slides and related Form 8-K filing with the SEC are available on the Investor Relations page of our website.
Speaking on today's call from Amedisys will be Paul Kusserow, Chairman and CEO; and Scott Ginn, CFO and Acting COO.
Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Amedisys today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws.
These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q and 8-K. In addition, as required by SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will also be available in our Forms 10-K, 10-Q and 8-K.
Thank you, and I'll turn the call over to Amedisys' Chairman and CEO, Paul Kusserow.
Paul Kusserow
Thanks, Nick. Hello, everyone, and welcome to the Amedisys Fourth Quarter and Year-end 2022 Earnings Call. It's a privilege to be back and talking to you all again. In a few short months I've been back as CEO, I've had the distinct pleasure of spending time in the field with our clinicians who provide the highest-quality care to their patients wherever they call home. What you do on a daily basis is truly inspiring and reaffirms to me more than ever that the future of Amedisys is extraordinary and unique.